Disclosures for "Long-term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved"
-
Mr. Dickson has nothing to disclose.
-
The institution of Mr. Whetten has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eisai.
-
Dr. Hendrix has received personal compensation for serving as an employee of Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pentara Corporation. The institution of Dr. Hendrix has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pentara Corporation. Dr. Hendrix has or had stock in Pentara.
-
Author has nothing to disclose
-
Dr. Jones has received personal compensation for serving as an employee of Eisai.